Related Experiment Video
Updated: Apr 23, 2026
06:24
Minimal Erythema Dose MED Testing
Published on: May 28, 2013
42.1K
[Ecchymosis during montelukast therapy: about one case]
Johana Béné1, Emeline Gantois2, Marion Landouzy2
1Centre régional de pharmacovigilance, Service de pharmacologie médicale, CHRU Lille, Lille, France.
Therapie
|October 2, 2014
Summary
A 13-year-old experienced unexplained bruises after starting montelukast, a common asthma medication. Switching to a generic form of montelukast resolved the bruising, suggesting a link between the drug and this side effect.
Area of Science:
- Pediatric Medicine
- Pharmacology
- Dermatology
Background:
- A 13-year-old female patient was undergoing treatment for respiratory conditions using a combination of medications.
- The patient's regimen included montelukast, fluticasone/salmeterol, desloratadine, fluticasone furoate, and salbutamol.
Observation:
- The patient developed numerous spontaneous bruises following the initiation of treatment.
- The onset of bruising was noted after montelukast was substituted with its generic formulation.
Findings:
- Discontinuation of montelukast led to a significant and noticeable improvement in the spontaneous bruising.
- This suggests a potential causal relationship between montelukast (or its generic form) and the development of bruising.
Implications:
- Montelukast, particularly its generic versions, may be associated with an increased risk of bruising in pediatric patients.
- Further investigation into the mechanism of montelukast-induced bruising is warranted.
- Clinicians should consider monitoring for and inquiring about bruising in patients prescribed montelukast.
